Nuvectis Pharma, Inc. (NVCT) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Fort Lee, NJ, 美国. 现任CEO为 Ron Bentsur.
NVCT 拥有 IPO日期为 2022-02-04, 13 名全职员工, 在 NASDAQ Capital Marke, 市值为 $231.27M.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
